BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32553770)

  • 21. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.
    Loungnarath R; Causeret S; Bossard N; Faheez M; Sayag-Beaujard AC; Brigand C; Gilly F; Glehen O
    Dis Colon Rectum; 2005 Jul; 48(7):1372-9. PubMed ID: 15909071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
    Witkamp AJ; de Bree E; Kaag MM; van Slooten GW; van Coevorden F; Zoetmulder FA
    Br J Surg; 2001 Mar; 88(3):458-63. PubMed ID: 11260116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation.
    Chua TC; Al-Zahrani A; Saxena A; Liauw W; Zhao J; Morris DL
    J Am Coll Surg; 2010 Oct; 211(4):526-35. PubMed ID: 20729102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cytoreductive Surgery Performed Twice for Pseudomyxoma Peritonei with Pleural Extension of Mucinous Tumor].
    Ito T; Yasuma F; Toyonaga Y; Kobayashi Y; Shinohara A; Furuya M; Shiga Y; Maehara Y
    Masui; 2015 Jun; 64(6):655-9. PubMed ID: 26437560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Sugarbaker PH
    Lancet Oncol; 2006 Jan; 7(1):69-76. PubMed ID: 16389186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
    Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
    Elias D; Gilly F; Quenet F; Bereder JM; Sidéris L; Mansvelt B; Lorimier G; Glehen O;
    Eur J Surg Oncol; 2010 May; 36(5):456-62. PubMed ID: 20227231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoreductive surgery plus bicavitary chemohyperthermia as treatment of pseudomixoma peritonei with pleural extension. A case report and review of the literature.
    Saladino E; Famulari C; La Monaca E; Fortugno A; Fleres F; Macrì A
    Ann Ital Chir; 2014; 85(4):372-6. PubMed ID: 25263588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review.
    Soucisse ML; Lansom J; Alshahrani MS; Morris DL
    ANZ J Surg; 2020 Oct; 90(10):1888-1894. PubMed ID: 32761790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
    Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
    Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
    Robella M; Vaira M; Borsano A; Mossetti C; DE Simone M
    Anticancer Res; 2018 Feb; 38(2):929-932. PubMed ID: 29374723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
    Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
    ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of pseudomyxoma peritonei using cytoreduction and intraperitoneal hyperthermic chemotherapy].
    Scuderi S; Costamagna D; Vaira M; Barone R; De Simone M
    Tumori; 2003; 89(4 Suppl):43-5. PubMed ID: 12903542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is a Prognostic Nomogram for Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Useful?
    Levine EA
    JAMA Surg; 2023 May; 158(5):531. PubMed ID: 36920379
    [No Abstract]   [Full Text] [Related]  

  • 39. Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
    Zoetmulder FA; Sugarbaker PH
    Eur J Cancer; 1996 Sep; 32A(10):1727-33. PubMed ID: 8983281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
    Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.